What are the top facts the antibody industry want to know?

Based on the agenda for the European Antibody Congress, what are you looking forward to learning/gaining from speaking at the congress and who from the speaking faculty are you most looking forward to hearing from, and why?

In a recent interview in association with the European Antibody Congress, we posed this question to 4 of our top speakers, and here is what they had to say:

“Based on the speaker’s agenda it appears that all of the talks are interesting and worth listening to. Antibody science is advancing in all areas so all the talks will help establish and orient others about current developments in the field.” Mark Glassy, CEO, Nascent Biologics

“In 2012 EAC features three parallel tracks with many informative talks and I know I will be torn making decisions which ones to attend. In addition, I am very much looking forward to plenary talks, panel discussions and networking with delegates.” Alexey Lugovskoy, Senior Director of Therapeutic Design, Merrimack Pharmaceuticals

“Paul Carter from Genentech because of the very rich pipeline.” Charles Dumontet, Co-Director, INSERM

“I am really interested in structure-function relationships and so I am looking forward to the talks of Alain Beck and Paul Carter.” Dietmar Reusch, Director Development Characterisation, Hoffmann-La Roche

DOWNLOAD the complete interviews and gain all the facts!

Want to find out more? Learn about :

New format European Antibody Congress 2012

Antibody development in the next 5 years

Antibodies: Top pre-clinical and clinical ADC programs from Pfizer

If you want to find out more then you need to attend the 8th annual European Antibody Congress – DOWNLOAD the brochure for the complete agenda.

For more updates on pharma, biotech and R&D, follow us on Twitter: @biopharmaevents or join our LinkedIn group: BioPharma- Networking for Pharmaceuticals, Biotech and R&D